Detection of novel actions of kampo medicines for lipid metabolism by lipidomic analysis

Boiogito (BOT) 的施用被证明可以改善饲喂补充胆酸盐 (CA) 饮食的小鼠的肝损伤。这种作用与肝脏甘油三酯（TG）含量减少的部分恢复有关。喂食补充 CA 的饮食的小鼠中，硬脂酰辅酶 A 去饱和酶 1 (SCD1) 的基因和蛋白质水平降低，而 BOT 给药则升高。这些结果表明，BOT 给药对 CA 诱导的肝损伤的改善可能是由于通过促进饱和脂肪酸的去饱和来恢复肝脏 TG 合成的减少，而饱和脂肪酸是肝脏中有效 TG 合成所必需的。另外，肝脏 TG 水平的降低可能是 BOT 改善 CA 诱导的肝损伤的结果。因此，我们的脂质组学分析揭示了在胆汁酸诱导的小鼠脂肪性肝炎期间汉方药物调节脂质代谢的新机制。

The administration of Boiogito (BOT) was shown to ameliorate liver injury in the mice fed a cholate (CA)-supplemenetd diet. This effect was associated with a partial restoration of the reduction in liver triglyceride (TG) content. The levels of gene and protein of stearoyl-CoA desaturase-1 (SCD1) were lowered in the mice fed the CA-supplemented diet, which were elevated by BOT administration. These results suggest that the amelioration of CA-induced liver injury by BOT administration may be due to the restoration of reduced synthesis of liver TG through the facilitation of desaturation of saturated fatty acids, which is required in the efficient TG synthesis in liver. Alternatively, the reduction in liver TG levels might be a consequence of the amelioration of CA-induced liver injury by BOT administration. Thus, our lipidomic analysis revealed a novel mechanism involved in the modulation of lipid metabolism by a kampo medicine during bile acid-induced steatohepatitis in the mice.